Rhythm Pharmaceuticals (RYTM) investor relations material

Strategic pillars and product focus

• Focused on three pillars: genetic obesity, hypothalamic obesity (HO), and Prader-Willi syndrome, with IMCIVREE as the lead product approved for multiple indications since 2020.

• Ongoing efforts to refine genetic targeting by identifying variants with true loss of function for higher trial success rates.

• Prader-Willi syndrome is a major future investment area, with significant development planned through 2027.

HO launch and market dynamics

• HO patients often lack a clear diagnosis and are managed by various specialists, creating challenges in awareness and identification.

• IMCIVREE has defined HO as a distinct entity, but awareness among endocrinologists remains modest.

• Expanded sales force to 42 for HO, targeting top-tier endocrinologists to drive adoption.

• Early launch saw 400+ start forms from 300 physicians, indicating broad-based interest.

• Education and patient identification remain key hurdles, with many patients undiagnosed or not yet engaged.

Payer and revenue trends

• No step edits required for reimbursement; payers adhere closely to the label.

• Data show patients with prior GLP-1 use respond well to IMCIVREE, supporting payer adoption.

• Revenue is becoming the primary metric for launch progress, with start forms shared in the near term.

• Rare disease launches are expected to grow steadily over time, without a sharp peak.